Navigation Links
Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
Date:6/4/2009

that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; and Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.<
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
2. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
3. First U.S. Patients Enrolled in the REALISM Continued Access Study
4. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
5. Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries
6. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
7. Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures
8. St. Jude Study Gives New Insights Into How Cells Accessorize Their Proteins
9. McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  BC Technical, the nation,s leading non-OEM provider ... a leader in sales, service and installation of GE ... Technical to continue to expand their resources and inventory ... modalities. "We are committed to driving ... , president and CEO of BC Technical. "We set ...
(Date:8/29/2014)... , August 29, 2014 ... Seed Oil Market by Extraction type (SFE, Cold ... & Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) ... by MarketsandMarkets, defines and segments the Amaranth Seed ... the market size in terms of value. The ...
(Date:8/29/2014)... Aug. 29, 2014   Vittamed Corporation , a neurodiagnostics ... announced today that T. (Teo) Forcht Dagi , MD, ... Board of Directors. " Teo Forcht Dagi ... neurosurgery, medical innovation and venture capital," said Remis Bistras ... to add his clinical, strategic, and entrepreneurial expertise to our ...
Breaking Medicine Technology:BC Technical Acquires Polaris Medical Imaging 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... its preliminary unaudited sales range for the third quarter ... full year 2010. A conference call to discuss these ... on October 25, 2010 at 8:00 a.m. Eastern Time ...
... Oct. 23 Optimer Pharmaceuticals, Inc. (Nasdaq: ... from its two fidaxomicin Phase 3 trials in patients ... 48th Annual Meeting of the Infectious Disease Society of ... oral presentation, investigator Derrick Crook, M.D., of the University ...
Cached Medicine Technology:Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations 2Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations 3Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 2Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 3Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 5
(Date:9/1/2014)... 2014 As well as having completed ... currently pursuing counselor certification in Louisiana. , ... CPI training program as well as the Counselor ... both personally and professionally. I am not only ... able to do so. As a Non Violent ...
(Date:9/1/2014)... York (PRWEB) September 01, 2014 ... retrieve, organize and analyze biological and genetic data. ... the activity of developing software tools to generate ... to be confused with biological computation. While bioinformatics ... understanding of biology can its related concepts, biological ...
(Date:9/1/2014)... Registration is now open for the 4th Annual ... to be held on Sunday, September 21, 2014. The event ... Meadow in Secaucus, New Jersey. All proceeds from the race ... to restoring a sense of self, restoring the family unit, ... families. , General registration is $30 with special pricing for ...
(Date:9/1/2014)... Daily Gossip reveals in it's review on Tattoo ... members access to thousands of professionally designed tattoo images ... to help both people who plan on getting a ... for inspiration in creating one of a kind models. ... visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 . , ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Pastor Thompson is ... Specialist at Eagle Village. He is a licensed minister through ... over the past twenty years in New Mexico, Colorado and ... years of marriage this year. He also has two ... a B.S. in Pastoral Ministry from Nazarene Bible College, in ...
Breaking Medicine News(10 mins):Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2
... experience have developed a weapon against one rapidly lethal war ... armor, where the trunk and legs join, to injure the ... within minutes. , "There is no way to ... in this area and dying within several minutes," said Dr. ...
... that previous models used to examine cancer may not ... environment. Using oral cancer cells in a three-dimensional model ... oral cavity, the researchers found that the tissue surrounding ... expression or suppression of a cell adhesion protein associated ...
... through hospital emergency departments and operated on within 48 ... by UK experts in anaesthesia, orthopaedics, geriatrics and emergency ... Anaesthesia . However, patients in one in ... than two days, risking lengthier inpatient stays, increased health ...
... Reporter , TUESDAY, Jan. 10 (HealthDay News) -- Unlike the ... declines in lung function that could lead to breathing problems, ... that road toward breathlessness, but low to moderate levels of ... there were limits to the study. For example, the findings ...
... sister with newly diagnosed cancer can be a distressing and ... there can be a period of adjustment when their school ... Central,s open access journal Child and Adolescent Psychiatry and ... improve the child,s knowledge about their sibling,s disease and to ...
... much more likely to develop mental health disorders as ... in clinical psychology at the University of Houston (UH) ... for Kids (SACK). To address this problem ... a clinical research center at UH that provides low-cost, ...
Cached Medicine News:Health News:Emergency medicine physicians develop device to stop lethal bleeding in soldiers 2Health News:Emergency medicine physicians develop device to stop lethal bleeding in soldiers 3Health News:Lab-made tissue picks up the slack of Petri dishes in cancer research 2Health News:Hip fracture guidelines tackle 'considerable variations' in UK and Irish hospital care 2Health News:Hip fracture guidelines tackle 'considerable variations' in UK and Irish hospital care 3Health News:Occasional Pot Smoking Won't Harm Lungs: Study 2Health News:Occasional Pot Smoking Won't Harm Lungs: Study 3Health News:New educational program helps the siblings of children with cancer 2Health News:University of Houston opens Sleep and Anxiety Center for Kids 2Health News:University of Houston opens Sleep and Anxiety Center for Kids 3
... stereopsis from 800 to 40 ... young as 2 years of ... from left to right., ,Randot ... Book #1: 200 & 100 ...
... The Standard for Stereo Depth Perception. ... 1200 sec or arc) and Fine ... Circle Test (800 to 40 sec ... (400 to 100 sec of arc), ...
The Emit Phenytoin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of phenytoin in human serum or plasma....
The Emit 2000 Phenytoin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of phenytoin in human serum or plasma. Kits are conveniently packaged in Olympus Reagent Cartrid...
Medicine Products: